top banner imagetop banner mobile image

Press Releases

Date Title
09/13/18
Summary ToggleTherapeuticsMD Announces Commercial Availability of Imvexxy™ 4 mcg
08/22/18
Summary ToggleTherapeuticsMD to Present at 13th Annual Wells Fargo Securities Healthcare Conference
08/10/18
Summary ToggleTherapeuticsMD Announces FDA Approval of ANNOVERA™ (Segesterone Acetate/Ethinyl Estradiol Vaginal System) for Birth Control
08/06/18
Summary ToggleTherapeuticsMD Announces Closing of its Underwritten Public Offering and Concurrent Registered Direct Offering of Common Stock
08/01/18
Summary ToggleTherapeuticsMD Announces Pricing of Its Underwritten Public Offering and Concurrent Registered Direct Offering for Aggregate Gross Proceeds of $85 Million
07/31/18
Summary ToggleTherapeuticsMD Licenses Population Council’s Novel Segesterone Acetate/ Ethinyl Estradiol One-Year Vaginal Contraceptive System
07/31/18
Summary ToggleKnight Therapeutics and TherapeuticsMD Announce Strategic Partnership
07/31/18
Summary ToggleTherapeuticsMD Announces Proposed $65 Million Underwritten Public Offering and Concurrent $20 Million Registered Direct Offering of Common Stock
07/30/18
Summary ToggleTherapeuticsMD Announces Second Quarter 2018 Financial Results
07/25/18
Summary ToggleTherapeuticsMD to Report Second Quarter 2018 Financial Results on July 30, 2018
06/07/18
Summary ToggleTherapeuticsMD Announces Draw Down of $75 Million Under Term Loan with MidCap Financial
06/07/18
Summary ToggleTherapeuticsMD to Present at Goldman Sachs 39th Annual Global Healthcare Conference
06/06/18
Summary ToggleTherapeuticsMD Announces Multiple Presentations at the International Menopause Society’s 16th World Congress
06/04/18
Summary ToggleTherapeuticsMD to Present at Jefferies 2018 Healthcare Conference
05/31/18
Summary ToggleTherapeuticsMD Announces Clinical Abstract at the 2018 ASCO Annual Meeting
05/30/18
Summary ToggleTherapeuticsMD Announces FDA Approval of TX-004HR: IMVEXXY™ (estradiol vaginal inserts), the Lowest Dose Vaginal Estrogen Product Approved for the Treatment of Moderate to Severe Dyspareunia, a Symptom of VVA, due to Menopause
05/23/18
Summary ToggleTherapeuticsMD Comments on Media Reports Regarding TX-004HR
05/16/18
Summary ToggleTherapeuticsMD Announces Investor and Analyst Day on June 4
05/03/18
Summary ToggleTherapeuticsMD Announces First Quarter 2018 Financial Results
05/01/18
Summary ToggleTherapeuticsMD to Host First Quarter Financial Results Conference Call and Webcast on May 3
04/11/18
Summary ToggleTherapeuticsMD Enters Into Label Negotiations for TX-004HR
04/02/18
Summary ToggleTherapeuticsMD Announces Expansion of Board of Directors
03/08/18
Summary ToggleTherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for TX-001HR
03/06/18
Summary ToggleTherapeuticsMD to Present at Two Upcoming Investor Conferences
02/20/18
Summary ToggleTherapeuticsMD Announces Fourth Quarter and Full Year 2017 Financial Results
02/06/18
Summary ToggleTherapeuticsMD to Host Fourth Quarter and Year End 2017 Financial Results Conference Call and Webcast on February 20
01/03/18
Summary ToggleTherapeuticsMD Announces Presentation at 36th Annual J.P. Morgan Healthcare Conference on January 10